{"id":526710,"date":"2021-01-19T06:50:01","date_gmt":"2021-01-19T06:50:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=526710"},"modified":"2021-01-19T06:50:01","modified_gmt":"2021-01-19T06:50:01","slug":"giantcell-arteritis-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/giantcell-arteritis-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast_526710.html","title":{"rendered":"Giant-Cell Arteritis Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast"},"content":{"rendered":"
\"Giant-Cell<\/a><\/p>\n
\n
Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Giant-Cell Arteritis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Giant-Cell Arteritis, historical and forecasted epidemiology as well as the Giant-Cell Arteritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

According to the National Centre for Advancing Translational Sciences” Giant-Cell Arteritis<\/strong> (GCA<\/strong>, also known as Temporal arteritis; Cranial Arteritis; Granulomatous Arteritis and Horton’s disease<\/strong>) is a form of vasculitis, a group of disorders that cause inflammation of blood vessels. GCA most commonly affects the arteries of the head (especially the temporal arteries, located on each side of the head), but arteries in other areas of the body can also become inflamed. The inflammation causes the arteries to narrow, resulting in poor blood flow”.<\/p>\n

The signs and symptoms of Giant Cell Arteritis<\/strong> are tenderness of the scalp, flu-like symptoms, problems with eyesight, and throbbing headache on one side or the back of the head. This happens when arteries in the head are involved.<\/p>\n

Get FREE sample copy at: 
<\/strong>https:\/\/www.delveinsight.com\/sample-request\/giant-cell-arteritis-market<\/strong><\/a><\/p>\n

The Giant-Cell Arteritis market<\/strong> report also covers emerging drugs, current treatment practices, Giant-Cell Arteritis market share of the individual therapies, current and forecasted Giant-Cell Arteritis Market Size from 2017 to 2030 segmented by seven major markets. <\/p>\n

The report provides a detailed current Giant-Cell Arteritis treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. <\/p>\n

\"Giant-Cell<\/p>\n

 <\/p>\n

Giant-Cell Arteritis Market Key Facts<\/strong><\/p>\n

According to the data of the Arthritis Foundation, Caucasian women over the age of 50 (most commonly between the ages of 70 and 80 years), have the highest risk of developing Giant-Cell Arteritis<\/strong>. Although women are more likely than men to develop GCA, research suggests that men are more likely to suffer potentially blinding eye involvement.<\/p>\n

Giant-Cell Arteritis occurs most frequently in populations of Northern Europe, and in particular in Scandinavian countries where the incidence has been reported as high as 32.8 per 100,000 inhabitants over the age of 50 years.<\/p>\n

According to the National Organization for Rare Diseases (NORD,), Giant-Cell Arteritis<\/strong> occurs in approximately 24 in 100,000 people over the age of 50 years, affecting twice as many females as males. Also, GCA affects 110,000 individuals in the United States.<\/p>\n

According to Ness et al. (2013) in an article titled “The Diagnosis and Treatment of Giant Cell Arteritis<\/strong>”, the incidence of GCA in Europe showed a marked north-south divide. In Germany, the incidence is stable at 3.5 per 100 000 inhabitants per year in the over-50 age group. Women are affected two to six times as often as men. After the age of 50, the incidence increases with age.<\/p>\n

Key Benefits of Giant-Cell Arteritis Market Report<\/strong><\/p>\n